Posted by Michael Wonder on 04 May 2020
China National Medical Products Administration approves Doptelet (avatrombopag) for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure
30 April 2020 - First approval for Doptelet in China and first-ever treatment for this indication in China.
AkaRx today announced Doptelet (avatrombopag) has been granted approval from the China National Medical Products Administration for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.
The approval was based on safety and efficacy data from two global Phase 3, double-blind, placebo-controlled trials, conducted in adults with severe thrombocytopenia (platelet count of less than 50,000/µL) and chronic liver disease.
